शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans
BSESyschem India Ltd· Pharmaceuticals & BiotechnologyHighNeutral
Announced Thu, 8 May, 2025 · 16:03 IST

Declaration of Financial results for the quarter and year ending 31st March, 2025

Revenue growth above 20%EBITDA margin compressionNegative operating cash flowRelated-party transactionsResults View source PDFExplain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-2.6%Reaction day
₹38.75
prior close
₹36.11
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used-0.1%-2.5% vs market
Pharmaceuticals peers, median of 146sector-0.2%-2.4% vs sector

On the reaction day the stock moved 2.5 pts less than Nifty Microcap 250 and 2.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+2.5
10m
+5.1
15m
+2.8
30m
+5.2
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-2.6-0.1-2.5-0.2-2.4
Next day
+5.6+4.5+1.1+2.4+3.2
2d
+6.2+6.2-0.0+4.0+2.2
3d
+7.1+7.9-0.8+4.4+2.7
4d
+6.8+9.0-2.2+5.1+1.7
5d
+4.9+9.9-4.9+5.5-0.5
1w
+5.3+10.0-4.7+5.5-0.2
15d
+21.0+13.1+7.9+7.0+14.0
1m
+19.3+15.5+3.8+7.8+11.5
2m
+18.9+16.8+2.1+8.7+10.2
3m
+17.8+11.3+6.5+2.5+15.3
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 146Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Syschem (India) Limited reported audited standalone results for FY25 with revenue from operations rising sharply to ₹386.23 crore from ₹233.48 crore in FY24, a growth of about 65%. However, profit before tax fell steeply to ₹1.01 crore from ₹4.11 crore, and profit after tax dropped to ₹46.01 lakh from ₹2.76 crore, reflecting heavy margin compression despite the strong top-line growth. The company raised ₹33.87 crore via a preferential issue in February-March 2025, partly deployed for working capital. Total financial indebtedness remains zero with no loan defaults reported, and cash and bank balances improved to ₹2.14 crore from ₹9.57 lakh a year ago.

Likely market impact

Strong revenue growth signals business expansion, but the sharp drop in profit and negative operating cash flow (₹10.09 crore used in operations) suggest cost pressures and working-capital strain, which may concern shareholders looking at profitability rather than just top-line numbers.